FDA Approval of LYNPARZA® in US for HRR gene-mutated mCRPC
Dr. Josefa Briceno, M.D., Medical Head for the DNA Damage Response Franchise in US Medical Affairs at AstraZeneca discusses the recent FDA approval of LYNPARZA® (olaparib) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Approval was based on results from the Phase III PROfound trial, which were published in the “New England Journal of Medicine”.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Briceno is a Surgical Oncologist by training who practiced for 13 years prior to working for AstraZeneca. At AZ she serves as the Medical Head for the DNA Damage Response (DDR) Franchise in US Medical Affairs, overseeing Lynparza across several indications, including Prostate Cancer.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
